ProQR Therapeutics (NASDAQ:PRQR) Director Bart Filius Acquires 150,000 Shares

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius acquired 150,000 shares of the business’s stock in a transaction on Friday, July 17th. The shares were bought at an average cost of $1.72 per share, with a total value of $258,000.00. Following the completion of the acquisition, the director owned 300,000 shares in the company, valued at approximately $516,000. This represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bart Filius also recently made the following trade(s):

• On Friday, June 26th, Bart Filius bought 150,000 shares of ProQR Therapeutics stock. The stock was purchased at an average cost of $1.54 per share, for a total transaction of $231,000.00.

ProQR Therapeutics Trading Up 1.7%

Shares of PRQR stock opened at $1.76 on Wednesday. The stock has a market capitalization of $185.43 million, a price-to-earnings ratio of -3.52 and a beta of 0.04. ProQR Therapeutics N.V. has a 12-month low of $1.33 and a 12-month high of $3.10. The stock’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.65.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting analysts’ consensus estimates of ($0.15). The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. As a group, research analysts predict that ProQR Therapeutics N.V. will post -0.52 EPS for the current fiscal year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Aberdeen Group plc increased its position in shares of ProQR Therapeutics by 28.4% during the 4th quarter. Aberdeen Group plc now owns 2,950,676 shares of the biopharmaceutical company’s stock valued at $5,960,000 after purchasing an additional 651,853 shares during the last quarter. Ikarian Capital LLC lifted its position in ProQR Therapeutics by 67.2% in the fourth quarter. Ikarian Capital LLC now owns 1,492,229 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 600,000 shares during the last quarter. Privium Fund Management B.V. lifted its position in ProQR Therapeutics by 7.2% in the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company’s stock worth $10,823,000 after buying an additional 359,475 shares during the last quarter. Citadel Advisors LLC boosted its stake in ProQR Therapeutics by 73.2% during the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 277,749 shares during the period. Finally, Millennium Management LLC boosted its stake in ProQR Therapeutics by 80.8% during the fourth quarter. Millennium Management LLC now owns 434,991 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 194,369 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on PRQR shares. JonesTrading lowered their target price on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, June 26th. Wall Street Zen downgraded shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Wednesday, May 27th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Finally, Chardan Capital dropped their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.